Feline Infectious Peritonitis (FIP) has long challenged veterinary professionals, with limited
treatment options and a historically poor prognosis for affected cats. In recent years,
antiviral therapy has become a more accessible and effective avenue for managing the
disease. Among the newer options being explored and adopted within the veterinary
compounding space is EIDD‑1931—an active antiviral compound showing promise in
treating FIP, particularly when conventional treatments are not accessible or suitable.
As the demand for more targeted and effective antivirals in veterinary medicine continues
to rise, EIDD‑1931 represents an important addition to the compounding pharmacist’s
toolkit. At MedicaPharma, we support veterinary professionals and compounding labs by
offering this compound with full traceability and regulatory documentation, sourced with
strict attention to quality and safety, even though it is not classified as a GMP-grade
material.
Download GMP-Certified API Product List
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations. Click here to download our complete API product list.
“Medicapharma’s products and services are exclusively available to licensed companies and professionals. We do not sell to individuals or private consumers.”
Get your requested raw materials quotation
Table of Contents
What is EIDD‑1931?
EIDD‑1931, also known as β-D-N4-hydroxycytidine, is the active metabolite of molnupiravir
(EIDD‑2801), a well-established antiviral originally developed for human use against RNA
viruses. By supplying the active form directly, EIDD‑1931 bypasses the need for in vivo
metabolic conversion, allowing for more predictable pharmacokinetics and potentially
enhanced efficacy in feline patients.
In practical application, EIDD‑1931 has shown a higher degree of antiviral activity—
estimated to be approximately four times more potent than its prodrug molnupiravir—while
maintaining a manageable toxicity profile when administered appropriately. This makes it
particularly attractive for veterinary professionals looking for second-line therapies or
alternatives in cases where other treatments such as GS‑441524 are not available or have
proven insufficient.
Get your requested raw materials quotation
Comparing EIDD‑1931 to GS‑441524
GS‑441524 remains the gold standard antiviral used in FIP treatment due to its welldocumented
safety and efficacy. However, its accessibility can be inconsistent across
certain regions, and costs may be a limiting factor for pet owners. In this context,
EIDD‑1931 provides a viable option—especially in cases of treatment resistance or
financial constraints.
While clinical data on EIDD‑1931 is more limited compared to GS‑441524, early field
reports and case series suggest that it can produce positive outcomes in cats with both
effusive and non-effusive forms of FIP. In some cases, it has been used to manage
neurological FIP at slightly higher doses. However, due to its higher potency and potential
for adverse effects at escalated dosing levels, EIDD‑1931 must be administered with
caution. Observed side effects have included neutropenia, skin and coat changes, reduced
appetite, and muscle wasting. For this reason, many veterinarians and pharmacists prefer
to reserve it for cases where GS‑441524 is ineffective or unavailable.
Get your requested raw materials quotation
Formulation and Use in Compounding
Veterinary compounding pharmacies using EIDD‑1931 benefit from the flexibility to tailor
dosage forms according to patient-specific needs. Whether for creating custom tablets,
oral suspensions, or other formulations, the compound’s stability and solubility make it an
adaptable option for individualized treatment plans.
Moreover, because it is the active form, EIDD‑1931 allows for direct formulation without
the need to account for bioactivation pathways, simplifying the pharmacological approach.
This directness may improve response times in acutely ill feline patients, though close
monitoring is always essential.
Transitioning from GS‑441524 to EIDD‑1931 is possible under veterinary supervision, and
in some treatment protocols, concurrent use has been documented. However, safety
monitoring, including bloodwork and observation for potential side effects, is vital
throughout treatment to ensure patient wellbeing.
Quality, Safety and Compliance: Why MedicaPharma is the Right Partner
Handling potent antivirals like EIDD‑1931 requires attention to both formulation integrity
and occupational safety. Proper handling protocols must be followed in the compounding
lab, and clear labeling, packaging, and documentation are necessary for downstream
compliance. This is especially true when dealing with veterinary treatments that may not
yet be approved under traditional pharmaceutical regulations in every jurisdiction.
At MedicaPharma, we provide full traceability, certificates of analysis, stability data, and
support documentation for all materials we supply—including EIDD‑1931. While it is not a
GMP-grade compound, it is sourced with rigorous attention to quality and consistency. Our
sourcing practices avoid repackaging or relabeling, ensuring integrity from original
production to end-user delivery.
In the case of a molecule like EIDD‑1931, which carries a high level of pharmacological
activity, confidence in documentation and quality controls is essential. We work closely
with our clients to ensure that every shipment meets the highest standards and that every
inquiry is answered with clarity and precision.
Meeting the Growing Need in Veterinary Antivirals
As veterinary medicine evolves to meet the complex health challenges facing today’s
companion animals, antiviral therapies like EIDD‑1931 will play a critical role. Whether as
an alternative treatment in resource-limited settings or as part of a broader antiviral
strategy in FIP cases, EIDD‑1931 offers potential benefits when used appropriately and
responsibly.
For compounding pharmacies seeking to expand their offering to veterinarians, adding
EIDD‑1931 to the formulary represents not only a practical solution but also a strategic
move. With the right sourcing partner, the integration of this compound into a veterinary
compounding practice can be seamless, safe, and clinically meaningful.
At MedicaPharma, we are proud to support veterinary health professionals with reliable
active ingredients backed by thorough documentation and a commitment to responsible
sourcing. EIDD‑1931 is just one example of how we help our partners stay ahead of
therapeutic trends and deliver life-changing solutions to the animals in their care.
Get a Fast and Easy GMP-Certified API Quote
Focus on your compounding pharmacy business and let MedicaPharma take care of your APIs. Obtaining a quote is easy
